Incretin-Based Drugs Don't Up Heart Failure Hospitalization Risk

Share this content:
Incretin-Based Drugs Don't Up Heart Failure Hospitalization Risk
Incretin-Based Drugs Don't Up Heart Failure Hospitalization Risk

THURSDAY, March 24, 2016 (HealthDay News) -- Incretin-based drugs are not associated with increased risk of hospitalization for heart failure, according to a study published in the March 24 issue of the New England Journal of Medicine.

Kristian B. Filion, Ph.D., from the Jewish General Hospital in Montreal, and colleagues used health care data from four Canadian provinces, the United States, and the United Kingdom to examine the risk of heart failure associated with antidiabetic incretin-based drugs. Each patient who was hospitalized for heart failure was matched with up to 20 controls from the same cohort in a nested case-control analysis. Data were included for 1,499,650 patients, with 29,741 hospitalized for heart failure.

The researchers observed no increase in the rate of hospitalization for heart failure with the use of incretin-based drugs versus oral antidiabetic-drug combinations among patients with a history of heart failure (hazard ratio, 0.86; 95 percent confidence interval, 0.62 to 1.19), or among those without heart failure history (hazard ratio, 0.82; 95 percent confidence interval, 0.67 to 1.00). Similar results were seen for dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 analogs.

"In this analysis of data from large cohorts of patients with diabetes, incretin-based drugs were not associated with an increased risk of hospitalization for heart failure, as compared with commonly used combinations of oral antidiabetic drugs," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »